Literature DB >> 16838143

Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease.

Renata D'Incà1, Elisabetta Dal Pont, Vincenza Di Leo, Antonio Ferronato, Walter Fries, Maria Grazia Vettorato, Diego Martines, Giacomo Carlo Sturniolo.   

Abstract

BACKGROUND AND AIMS: Calprotectin and lactoferrin are specific neutrophil-derived proteins, which can be measured in the feces because they are released by cells in inflammatory conditions. We evaluated the efficacy of calprotectin and lactoferrin in detecting organic disease as assessed by colonoscopy.
METHODS: The study comprised 144 patients undergoing colonoscopy for lower gastrointestinal symptoms (abdominal pain, altered bowel habits, and bloody stools) (67), or inflammatory bowel disease activity, or surveillance for dysplasia (77). A single stool sample was assayed for calprotectin and lactoferrin. The proportion of patients correctly diagnosed with each test and the relationship with endoscopic and histological findings were measured.
RESULTS: Fecal excretion of calprotectin significantly correlated with the finding of colonic inflammation at endoscopy, both in ulcerative colitis and in Crohn's disease (p<0,001 and p<0,008, respectively), while lactoferrin excretion significantly correlated with histological inflammation (p=0.001 and p=0.009 respectively). Recommended cut-off values need to be adjusted in the inflammatory bowel disease group. Overall sensitivity, specificity, positive predictive value, and diagnostic efficacy were 78, 83, 86, and 80% for calprotectin and 80, 85, 87, and 81% for lactoferrin, respectively.
CONCLUSIONS: Fecal calprotectin and lactoferrin appear to be equally recommendable as inflammatory disease markers in patients with lower gastrointestinal symptoms. Both tests are needed to accurately discriminate activity in inflammatory bowel disease patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16838143     DOI: 10.1007/s00384-006-0159-9

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  34 in total

1.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study.

Authors:  A G Røseth; M K Fagerhol; E Aadland; H Schjønsby
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

2.  Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis.

Authors:  Jost Langhorst; Sigrid Elsenbruch; Twyla Mueller; Andreas Rueffer; Guenther Spahn; Andreas Michalsen; Gustav J Dobos
Journal:  Inflamm Bowel Dis       Date:  2005-12       Impact factor: 5.325

3.  Faecal calprotectin levels in a high risk population for colorectal neoplasia.

Authors:  O Kronborg; M Ugstad; P Fuglerud; B Johne; J Hardcastle; J H Scholefield; K Vellacott; V Moshakis; J R Reynolds
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

4.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.

Authors:  J A Tibble; G Sigthorsson; S Bridger; M K Fagerhol; I Bjarnason
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

5.  Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease.

Authors:  A G Røseth; P N Schmidt; M K Fagerhol
Journal:  Scand J Gastroenterol       Date:  1999-01       Impact factor: 2.423

6.  Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis.

Authors:  Hiroyuki Hanai; Ken Takeuchi; Takayuki Iida; Nobuhito Kashiwagi; Abby R Saniabadi; Isao Matsushita; Yoshihiko Sato; Naoki Kasuga; Toshihiro Nakamura
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

7.  Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea.

Authors:  K D Fine; F Ogunji; J George; M D Niehaus; R L Guerrant
Journal:  Am J Gastroenterol       Date:  1998-08       Impact factor: 10.864

8.  Faecal calprotectin: a novel test for the diagnosis of colorectal cancer?

Authors:  A G Røseth; J Kristinsson; M K Fagerhol; H Schjønsby; E Aadland; K Nygaard; B Roald
Journal:  Scand J Gastroenterol       Date:  1993-12       Impact factor: 2.423

9.  Fecal lactoferrin: a new parameter to monitor infliximab therapy.

Authors:  Stephan Buderus; James Boone; David Lyerly; Michael J Lentze
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

10.  Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins.

Authors:  K Sugi; O Saitoh; I Hirata; K Katsu
Journal:  Am J Gastroenterol       Date:  1996-05       Impact factor: 10.864

View more
  60 in total

Review 1.  Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis.

Authors:  Yan Wang; Fengyan Pei; Xingjuan Wang; Zhiyu Sun; Chengjin Hu; Hengli Dou
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 2.  Enteric infections, diarrhea, and their impact on function and development.

Authors:  William A Petri; Mark Miller; Henry J Binder; Myron M Levine; Rebecca Dillingham; Richard L Guerrant
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

3.  Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse.

Authors:  Asuka Nakarai; Jun Kato; Sakiko Hiraoka; Shiho Takashima; Daisuke Takei; Toshihiro Inokuchi; Yuusaku Sugihara; Masahiro Takahara; Keita Harada; Hiroyuki Okada
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

Review 4.  Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis.

Authors:  M L Stoll
Journal:  Clin Exp Rheumatol       Date:  2011-04-19       Impact factor: 4.473

Review 5.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

6.  Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammation.

Authors:  Raffaele Pezzilli; Alessandra Barassi; Antonio M Morselli-Labate; Lorenzo Fantini; Paola Tomassetti; Davide Campana; Riccardo Casadei; Sergio Finazzi; Gianvico Melzi d'Eril; Roberto Corinaldesi
Journal:  J Gastroenterol       Date:  2007-09-25       Impact factor: 7.527

7.  Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease.

Authors:  Michael Wagner; Christer G B Peterson; Peter Ridefelt; Per Sangfelt; Marie Carlson
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

8.  Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma.

Authors:  Frank Serge Lehmann; Francesca Trapani; Ida Fueglistaler; Luigi Maria Terracciano; Markus von Flüe; Gieri Cathomas; Andreas Zettl; Pascal Benkert; Daniel Oertli; Christoph Beglinger
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

9.  Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes.

Authors:  Andrea Vieira; Chia Bin Fang; Ernani Geraldo Rolim; Wilmar Artur Klug; Flávio Steinwurz; Lucio Giovanni Battista Rossini; Paulo Azevedo Candelária
Journal:  BMC Res Notes       Date:  2009-10-29

Review 10.  Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.

Authors:  Jan Däbritz; Jason Musci; Dirk Foell
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.